INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY

被引：0
|
作者：
Minard-Colin, V.
Auperin, A.
Burke, A.
Alexander, S.
Moreno, M.
Buffardi, S.
Uyttebroeck, A.
Bollard, C.
Zsiros, J.
Csoka, M.
Kazanowska, B.
Chiang, A.
Verschuur, A.
Miles, R.
Wotherspoon, A.
Barkauskas, D.
Wheatley, K.
Vassal, G.
Adamson, P.
Gross, T.
Patte, C.
Pillon, M.
机构：
来源：
LEUKEMIA RESEARCH | 2022年 / 121卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
061
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [41] Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial
    Cairo, M. S.
    Sposto, R.
    Gerrard, M.
    Waxman, I.
    Goldman, S.
    Auperin, A.
    Pinkerton, R.
    Raphael, M.
    McCarthy, K.
    Perkins, S. L.
    Patte, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] RITUXIMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY FOR HIGH-RISK MATURE B-CELL NON-HODKIN′S LYMPHOMA IN CHILDREN: THE JPLSG B-NH14 TRIAL
    Mori, Tetsuya
    Osumi, Tomoo
    Kada, Akiko
    Saito, Akiko
    Nakazawa, Atsuko
    Kobayashi, Ryoji
    Sekimizu, Masahiro
    PEDIATRIC BLOOD & CANCER, 2024, 71 : S72 - S72
  • [43] THE EFFICACY OF RASBURICASE DURING REDUCTION COP CHEMOTHERAPY FOR THE PREVENTION OF TUMOR LYSIS SYNDROME (TLS) IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED STAGE III/IV, BM+ AND CNS+ MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Hochberg, Jessica
    Galardy, Paul
    Goldman, Stanton
    Smith, Lynette
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2012, 58 (07) : 1041 - 1041
  • [44] Preliminary results of a phase II study of chemoimmunotherapy (rituximab plus FAB chemotherapy) in children and adolescents with intermediate risk B-cell NHL: A children's oncology group report
    Goldman, S.
    Lynch, J.
    Davenport, V.
    Perkins, S.
    Shiramizu, B.
    Sanger, W.
    Gross, T.
    Harrison, L.
    Bancroft, M.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 110
  • [45] Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1
    Frazer, J. Kimble
    Li, Kevin J.
    Galardy, Paul J.
    Perkins, Sherrie L.
    Auperin, Anne
    Anderson, James R.
    Pinkerton, Ross
    Buxton, Allen
    Gross, Thomas G.
    Michon, Jean
    Leverger, Guy
    Weinstein, Howard J.
    Harrison, Lauren
    Shiramizu, Bruce
    Barth, Mathew J.
    Goldman, Stanton C.
    Patte, Catherine
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) : 374 - 377
  • [46] Efficacy of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients
    Schwarzbich, M-A
    Schoening, T.
    Maximillian, M.
    Ho, A. D.
    Witzens-Harig, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 142 - 142
  • [47] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48
  • [48] Rituximab combined with DexaBEAM as salvage therapy followed by high dose therapy (HDT) in patients with relapsed or refractory B-NHL: high response rates and sustained remissions - mature results of a phase II multicenter study
    Kirschey, S.
    Flohr, T.
    Schulz, A.
    Kolbe, K.
    Derigs, H-G
    Theobald, M.
    Hess, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 146 - 146
  • [49] Efficacy and safety of pediatric treatment for adolescent patients with mature B-cell Non-Hodgkin's lymphoma treated on Japanese pediatric leukemia/lymphoma study Group (JPLSG) clinical trial (B-NHL03)
    Sekimizu, Masahiro
    Hashimoto, Hiroya
    Mori, Tetsuya
    Kobayashi, Ryoji
    Horibe, Keizo
    Tsurusawa, Masahito
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 78 - 78
  • [50] EXCELLENT OUTCOME IN CNS-POSITIVE PEDIATRIC BURKITT LYMPHOMA AND OTHER MATURE B-NHL TREATED WITH COMBINED CHEMO-IMMUNOTHERAPY (RITUXIMAB plus FAB GROUP C) WITHOUT CNS RADIATION: A CHILDREN'S ONCOLOGY GROUP REPORT
    Frazer, J. K.
    Goldman, S.
    Harrison, L.
    Perkins, S. L.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 177 - 177
12345